| Nov 18 |
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
|
| Nov 15 |
CNS Pharmaceuticals reports Q3 results
|
| Nov 15 |
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
|
| Nov 4 |
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
|
| Nov 1 |
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
|
| Oct 23 |
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Oct 10 |
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
|
| Oct 8 |
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
|
| Sep 23 |
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
|
